ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 048

Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

Orly Ohana1, Itay Marmor2, Liora Harel3, Shiri Rubin4, rotem tal5, Yoel Levinsky6, Orit Peled7 and Gil Amarilyo3, 1Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, 2Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, 4Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 6Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 7Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: , , ,

Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include gastrointestinal ulcers/bleeding and impaired renal function.

The most prescribed NSAIDs for oJIA are ibuprofen (IBU) and naproxen (NAP). However, direct comparison between these drugs is lacking. We aimed to compare the efficacy and safety of IBU vs. NAP for oJIA.

Methods: This is bi-national retrospective study of oJIA patients from Schneider Childrens Medical Center (SCMCI) and in St. Louis Children’s Hospital (STL) treated with either IBU or NAP as first-line therapy. Efficacy was defined as patients that achieved complete response (CR=no evidence for arthritis). Safety was assessed by the occurrence of AEs during follow-up.

Results: Of 171 patients, 104 were treated in SCMCI and 67 in STL. The study population had a mean age of 4.48 years, with female/male ratio ~2.5:1 (71.9% vs. 28.1%). 110 patients (64%) were treated with NAP and 61 (36%) with IBU. No significant difference was found in drug efficacy [CR 10/61 (16.4%) IBU vs. 19/110 (17.3%) NAP (P=0.83)]. Treatment duration 28 days was associated with significantly higher odds for CR (p=0.017). For safety, 13 AEs were associated with NAP, whereas only one for IBU (p=0.02). Treatment was discontinued in all AEs cases.

Conclusion: IBU and NAP showed similar albeit low efficacy which emphasizes their role as bridging therapy until IACI is achieved. However, IBU showed better safety profile NAP and therefore should be considered as first-line therapy.

Disclosures: O. Ohana: None; I. Marmor: None; L. Harel: None; S. Rubin: None; r. tal: None; Y. Levinsky: None; O. Peled: None; G. Amarilyo: None.

To cite this abstract in AMA style:

Ohana O, Marmor I, Harel L, Rubin S, tal r, Levinsky Y, Peled O, Amarilyo G. Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-ibuprofen-and-naproxen-in-the-treatment-of-oligoarticular-juvenile-idiopathic-arthritis-ojia-bi-national-cohort-study/. Accessed .

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-ibuprofen-and-naproxen-in-the-treatment-of-oligoarticular-juvenile-idiopathic-arthritis-ojia-bi-national-cohort-study/